Tick what the program you are considering actually discloses on its own site — not what a review says about it. Two of the six are disqualifying on their own: a program that guarantees approval before a clinician has seen your history, or that does not require a prescription, is not running a clinical process.
This scores disclosure, not safety. A program can pass every check and still ship late. What passing buys you is the ability to verify things yourself before money changes hands.
Why these six
They are the checks that are answerable before you pay, from public information, without clinical training. Pharmacy identity carries the most weight because it is the one fact that lets you check a state board register yourself.
What this cannot tell you
Whether shipments arrive on time, whether support answers, or whether the clinical oversight is good. Those need patient reports and time, and no checklist substitutes for them.
If a program fails
Ask for the missing items in writing. A program that answers is behaving well; one that deflects the pharmacy question has told you what you needed to know.
Frequently asked questions
Does a high score mean it is safe?
No. It means the program publishes what you need to verify it yourself. Safety depends on the pharmacy, the prescriber and the supply chain behind it.
Which check matters most?
The pharmacy name. It is the only one that lets you check a public state board register before you inject anything weekly.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.